Welcome to our dedicated page for COLUMBUS CIRCLE CAP II SEC filings (Ticker: CMIIU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CM Life Sciences II Inc. is a blank check company formed for the purpose of effecting a business combination. The Company intends to focus its search for business combination targets in three separate areas of the life sciences industry that are often fragmented – life sciences tools, synthetic biology and diagnostics.Columbus Circle Capital Corp filed its annual report outlining its status as a newly formed SPAC with no operating revenues and no Business Combination target yet selected. The company completed an IPO of 23,000,000 units at $10.00 each, raising gross proceeds of $230,000,000, and a concurrent private placement of 665,000 units for $6,650,000.
A total of $230,000,000 from the IPO and private placement was placed in a trust account to fund a future Business Combination, with public shareholders entitled to redeem at about $10.00 per share. The SPAC must complete a Business Combination by February 12, 2028 or liquidate and return trust funds to public shareholders.
As of March 30, 2026 there were 23,665,000 Class A ordinary shares and 7,666,667 Class B ordinary shares outstanding. The filing highlights substantial potential dilution from founder shares, private placement units, working capital loans convertible into up to 150,000 additional private Class A shares, and associated warrants exercisable at $11.50 per share.
Columbus Circle Capital Corp II is allowing investors to trade its Class A ordinary shares and warrants separately from its units. Starting February 27, 2026, each unit, which includes one Class A ordinary share and one-third of a redeemable warrant, can be split.
Whole warrants will trade under the symbol CMIIW, with each whole warrant exercisable to buy one Class A ordinary share at $11.50 per share. The Class A ordinary shares will trade under CMII, while any unsplit units will continue to trade under CMIIU on the Nasdaq Global Market.
Columbus Circle 2 Sponsor Corporation LLC and affiliates report beneficial ownership of 7,931,667 Ordinary Shares, or 25.3%, of Columbus Circle Capital Corp II. This stake consists of 7,666,667 Class B “founder” shares bought for $25,000 and 265,000 Class A shares within private placement units purchased for $10.00 per unit.
The sponsor group invested a total of $2,675,000 and holds significant voting and disposition power over these shares. They have agreed to vote their founder and placement shares in favor of any initial business combination, not redeem their shares in related votes, and accept lock-up and non-liquidation terms customary for SPAC sponsors, including an indemnity to protect the trust account at $10.00 per public share.
Columbus Circle Capital Corp II completed its initial public offering of 23,000,000 units at $10.00 per unit, raising $230,000,000 in gross proceeds. Each unit includes one Class A ordinary share and one-third of a redeemable warrant exercisable at $11.50 per share.
The company also sold 665,000 Private Placement Units for $6,650,000, and a total of $230,000,000 was placed in a U.S. trust account. The balance sheet shows total assets of $231,848,494, including $1,664,554 of cash outside the trust and 23,000,000 Class A shares recorded at a $10.00 redemption value.
Governance changes include the resignation of Adam Back from the board and his committee roles, and the appointment of Marc Spiegel to the Audit and Compensation Committees. As a blank check company, Columbus Circle Capital Corp II now has up to 24 months from IPO closing to complete a business combination or return funds to public shareholders.
Columbus Circle Capital Corp II reported that Columbus Circle 2 Sponsor Corporation LLC acquired 265,000 Class A ordinary shares on February 12, 2026. The transaction was coded as an open-market or private purchase at a price of $10.0000 per share, leaving 265,000 shares owned following the transaction.
The shares represent units, with each unit consisting of one Class A ordinary share and one-third of one warrant, with each whole warrant exercisable for one Class A ordinary share. The units were acquired under a Private Placement Units Purchase Agreement between the Sponsor and the issuer.
Cohen & Company, LLC, as managing member of the Sponsor, holds voting and investment discretion over these securities, and Cohen & Company Inc. controls the Sponsor through subsidiaries. Both Cohen entities disclaim beneficial ownership beyond any pecuniary interest. The disclosure notes an additional 7,666,667 Class B ordinary shares that are separate from this transaction and are expected to convert into Class A ordinary shares in connection with the issuer's initial business combination.